Filed Pursuant to Rule 433
Issuer Free Writing Prospectus dated February 11, 2014
Relating to Preliminary Prospectus dated February 10, 2014
Registration No. 333-193681
2,285,714 Shares
Common Stock
This free writing prospectus relates only to the shares of common stock of Ophthotech Corporation described below and should be read together with the preliminary prospectus dated February 10, 2014 (the “Preliminary Prospectus”) included in Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-193681) relating to these shares.
The following information supplements and updates the information contained in the Preliminary Prospectus.
|
Common Stock Offered by Ophthotech Corporation |
|
1,900,000 shares | |||||
|
|
|
| |||||
|
Common Stock Offered by Selling Stockholders |
|
385,714 shares | |||||
|
|
|
| |||||
|
Common Stock to be Outstanding After This Offering |
|
33,318,575 shares | |||||
|
|
|
| |||||
|
Option to Purchase Additional Shares Granted by the Selling Stockholders |
|
342,857 shares | |||||
|
|
|
| |||||
|
Public Offering Price |
|
$31.50 | |||||
|
|
|
| |||||
|
Selling Stockholder Information |
|
Selling Stockholder |
|
Number of |
|
Additional Shares to be Sold if Underwriters’ Option is Exercised in Full |
|
|
|
|
Entities Affiliated with SV Life Sciences |
|
372,594 |
|
331,194 |
|
|
|
|
International Biotechnology Trust plc |
|
13,120 |
|
11,663 |
|
The issuer has filed a registration statement (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717.